Key result
Rapid acetylator status did not significantly alter the hemodynamic effects of levosimendan compared to slow acetylators, with similar changes in cardiac output (+2.0 vs. +1.6 l/min, p=0.309).
Why the study?
Does acetylator status affect the hemodynamic responses after levosimendan infusion in patients with NYHA III to IV heart failure?
Cohort (n=41)
Does acetylator status affect the hemodynamic responses after levosimendan infusion in patients with NYHA III to IV heart failure?
Absolute Event Rate: 2% vs 1.6%
p-value: p=0.309
The sustained hemodynamic effects of levosimendan in heart failure patients are not affected by the patient's acetylator status, despite differences in active metabolite levels.
No takes yet. Share an insight, caveat, or question.
Acetylator status should not yet guide levosimendan dosing in advanced HF; hypothesis-generating for metabolite-independent hemodynamic effects.
Kivikko et al. (2010) conducted a cohort in NYHA III to IV heart failure (n=41). Rapid acetylator status vs. Slow acetylator status was evaluated on Change from baseline in cardiac output (p=0.309). Rapid acetylator status did not significantly alter the hemodynamic effects of levosimendan compared to slow acetylators, with similar changes in cardiac output (+2.0 vs. +1.6 l/min, p=0.309).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: